Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 228

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor–Positive Early Breast Cancer: PALLET Trial

Open access
Johnston, Stephen, Puhalla, Shannon, Wheatley, Duncan, Ring, Alistair, Barry, Peter, Holcombe, Chris, Boileau, Jean Francois, Provencher, Louise, Robidoux, André, Rimawi, Mothaffar, McIntosh, Stuart A., Shalaby, Ibrahim, Stein, Robert C., Thirlwell, Michael, Dolling, David, Morden, James, Snowdon, Claire, Perry, Sophie, Cornman, Chester, Batten, Leona M., Jeffs, Lisa K., Dodson, Andrew, Martins, Vera, Modi, Arjun, Osborne, C. Kent, Pogue-Geile, Katherine L., Cheang, Maggie Chon U, Wolmark, Norman, Julian, Thomas B., Fisher, Kate, MacKenzie, Mairead, Wilcox, Maggie, Huang Bartlett, Cynthia, Koehler, Maria, Dowsett, Mitch, Bliss, Judith M., Jacobs, Samuel A. · 2019 · Journal of Clinical Oncology

Abstract

PURPOSE: CDK4/6 inhibitors are used to treat estrogen receptor (ER)–positive metastatic breast cancer (BC) in combination with endocrine therapy. PALLET is a phase II randomized trial that evaluated the effects of combination palbociclib plus letrozole as neoadjuvant therapy. PATIENTS AND METHODS: Postmenopausal women with ER-positive primary BC and tumors greater than or equal to 2.0 cm were randomly assigned 3:2:2:2 to letrozole (2.5 mg/d) for 14 weeks (A); letrozole for 2 weeks, then palbociclib plus letrozole to 14 weeks (B); palbociclib for 2 weeks, then palbociclib plus letrozole to 14 weeks (C); or palbociclib plus letrozole for 14 weeks. Palbociclib 125 mg/d was administered orally on a 21-days-on, 7-days-off schedule. Core-cut biopsies were taken at baseline and 2 and 14 weeks. Coprimary end points for letrozole versus palbociclib plus letrozole groups (A v B + C + D) were change in Ki-67 (protein encoded by the MKI67 gene; immunohistochemistry) between baseline and 14 weeks and clinical response (ordinal and ultrasound) after 14 weeks. Complete cell-cycle arrest was defined as Ki-67 less than or equal to 2.7%. Apoptosis was characterized by cleaved poly (ADP-ribose) polymerase. RESULTS: Three hundred seven patients were recruited. Clinical response was not significantly different between palbociclib plus letrozole and letrozole groups ( P = .20; complete response + partial response, 54.3% v 49.5%), and progressive disease was 3.2% versus 5.4%, respectively. Median log-fold change in Ki-67 was greater with palbociclib plus letrozole compared with letrozole (−4.1 v −2.2; P < .001) in the 190 evaluable patients (61.9%), corresponding to a geometric mean change of −97.4% versus −88.5%. More patients on palbociclib plus letrozole achieved complete cell-cycle arrest (90% v 59%; P < .001). Median log-fold change (suppression) of cleaved poly (ADP-ribose) polymerase was greater with palbociclib plus letrozole versus letrozole (−0.80 v −0.42; P < .001). More patients had grade 3 or greater toxicity on palbociclib plus letrozole (49.8% v 17.0%; P < .001) mainly because of asymptomatic neutropenia. CONCLUSION: Adding palbociclib to letrozole significantly enhanced the suppression of malignant cell proliferation (Ki-67) in primary ER-positive BC, but did not increase the clinical response rate over 14 weeks, which was possibly related to a concurrent reduction in apoptosis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.18.01624

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 228

Metadata

Authors
Johnston, S., Puhalla, S., Wheatley, D., Ring, A., Barry, P., Holcombe, C., Boileau, J. F., Provencher, L., Robidoux, A., Rimawi, M., McIntosh, S. A., Shalaby, I., Stein, R. C., Thirlwell, M., Dolling, D., Morden, J., Snowdon, C., Perry, S., Cornman, C., Batten, L. M., Jeffs, L. K., Dodson, A., Martins, V., Modi, A., Osborne, C. K., Pogue-Geile, K. L., Cheang, M. C. U., Wolmark, N., Julian, T. B., Fisher, K., MacKenzie, M., Wilcox, M., Huang Bartlett, C., Koehler, M., Dowsett, M., Bliss, J. M., & Jacobs, S. A.
Venue
Journal of Clinical Oncology
Published
2019-01-20
Volume
37
Issue
3
Pages
178-189
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2902672529
Cited by
228
References
9
FWCI
15.56
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.